Clinilabs Expands Phase I Facility
Clinilabs, Inc., a specialty contract research organization (CRO), has completed expansion of its Phase I unit.
CLINILABS EXPANDS PHASE I FACILITY
New York, NY (August 6, 2008) – Clinilabs, Inc., a specialty contract research organization (CRO), has completed expansion of its Phase I unit. This expansion brings the Company’s Phase I facility to 68-beds, which includes two new large observation rooms that can accommodate up to four beds each, or up to 12 PK seats.
The Company conducts Phase I studies in any therapeutic area, including pharmacokinetic (PK), pharmacodynamic (PD), bioavailability (BA), bioequivalence (BE), drug interaction, and food interaction studies. Additionally, Clinilabs offers specialty services for complex PD studies, such as those that involve the collection of mood, cognition, psychomotor functioning, EEG, quantitative EEG, evoked potential (EP), and imaging data.
“Phase I studies are becoming increasingly complex and sponsors depend on data from these studies to make crucial decisions about their development programs,” stated Dr. Gary Zammit, President and CEO of Clinilabs. “Clinilabs’ state-of-the-art facility is an ideal location for pharmaceutical and biotechnology companies looking for outstanding service for their Phase I studies,” he added.
Conveniently located in New York City, Clinilabs can recruit patients from a large and diverse population, including healthy adult, healthy elderly, Japanese, Chinese, and key patient populations. In addition, Clinilabs’ metropolitan location provides sponsors, as well as patients, with easy access to transportation hubs and major subway and bus lines.
Clinilabs Phase I facility is staffed with highly qualified physicians, nurses, and research associates, providing service 24 hours a day, 7 days a week.
About Clinilabs, Inc.
Clinilabs is a specialty contract research organization (CRO) that provides a full portfolio of services to pharmaceutical, biotechnology, and medical device companies involved in the development of central nervous system (CNS) and cardiovascular (CV) therapeutics. The Company also provides early phase services in a wider range of therapeutic areas at its Phase I facility. Established in 2001, Clinilabs has provided services to more than one third of the world’s top 20 pharmaceutical companies, and has been involved in 7 successful New Drug Applications (NDAs) in central nervous system (CNS) and cardiovascular (CV) indications. For more information, please visit www.clinilabs.com <
http://www.clinilabs.com/
> .
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
